0
Abstract: Poster Presentations |

LONG-TERM EFFICACY OF TRANSCATHETER PATENT FORAMEN OVALE (PFO) CLOSURE IN RELIEF OF MIGRAINE HEADACHE WITH AURA FREE TO VIEW

Irfan Siddiqui, DO; Arbind Behura, MD; Noman Hussain, MD; Aaref Badshah, MD*
Author and Funding Information

Saint Joseph Mercy-Oakland, Pontiac, MI


Chest


Chest. 2009;136(4_MeetingAbstracts):106S-b-107S. doi:10.1378/chest.136.4_MeetingAbstracts.106S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  To assess the long term efficacy of transcatheter Patent foramen ovale closure on migraine headache with aura (MHA) frequency in a 12 month follow-up period.

METHODS:  During an approximate 3-year time period, 37 patients presented for evaluation of trans-catheter PFO closure for prevention of cryptogenic stroke or transient ischemic attack (TIA) and were known to suffer from migraine headaches with aura (MHA). A one-year retrospective analysis of migraine symptoms before and after PFO closure was performed. A total of 33 subjects fulfilled the inclusion criteria. The incidence and severity of Migraine headache with aura was assessed using Migraine Disability Assessment (MIDAS) questionnaire. Transesophageal echocardiography (TEE) and Trans-cranial Doppler (TCD) were used to assess the presence and magnitudes of the Right-to-Left shunt in all 33 subjects (100%).

RESULTS:  Patients with MHA were found to have a higher prevalence of spontaneous R-to-L shunt and of spontaneous larger shunt, evident both at transesophageal echocardiography (P = .015, and .028, respectively) and at TCD (P = .036, and .038, respectively). Immediately post catheter PFO closure, 85% (28/33) of the subjects reported either complete resolution or a significant improvement in their MHA. At a mean follow-up of 12 months, MHA disappeared completely in 79% (26/33) of subjects. Of the remaining 7 subjects, 3 were found to have an improvement of ≥ 2 grades in the incidence and severity of MHA, 2 failed to show any improvement at all, whereas 2 subjects reported severe relapse of MHA about 12 months after the procedure.

CONCLUSION:  In patients who suffer from MHA and are found to have a PFO, trans-catheter closure of their septal defect results in complete resolution or marked reduction in the frequency of their migraine attacks.At long-term follow-up, the rate of recurrence remains low.

CLINICAL IMPLICATIONS:  Trans-catheter defect closure seems to be an effective and safe means to treat MHA in patients with PFO.The positive effects of transcatheter PFO closure for the prevention and treatment of MHA seem to be maintained in long-term followup.

DISCLOSURE:  Aaref Badshah, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, November 4, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543